Table 1 Baseline characteristics of two groups
characteristics | anlotinib monotherapy | anlotinib combination | P value |
|---|---|---|---|
Age | 68.1 ± 9.4 | 66.3 ± 10 | 0.464 |
Gender, n(%) | Â | Â | 0.638 |
 Male | 24(80) | 24(75) |  |
 Female | 6(20) | 8(25) |  |
Histology, n(%) | Â | Â | 0.328 |
 Squamous cell carcinoma | 15(50) | 14(43.8) |  |
 Non-squamous cell carcinoma | 15(50) | 18(56.2) |  |
ECOG, n(%) | Â | Â | 0.328 |
 0 | 18(60) | 18(56.2) |  |
 1 | 12(40) | 14(43.8) |  |
Metastasis, n(%) | Â | Â | 0.364 |
 No | 15(50) | 11(34.4) |  |
 Number of metastases = 1 | 9(30) | 10(31.3) |  |
 Number of metastases = 2 | 4(13.3) | 10(31.2) |  |
 Number of metastases ≥ 3 | 2(6.7) | 1(3.1) |  |
Hypertension, n(%) | Â | Â | 0.461 |
 No | 19(63.3) | 17(53.1) |  |
 Yes | 11(36.7) | 15(46.9) |  |
Treatment line, n(%) | Â | Â | 0.526 |
 First-line | 5(16.7) | 6(18.8) |  |
 Second-line | 6(20) | 10(31.2) |  |
 Third-line and above | 19(63.3) | 16(50) |  |
Pre-antiangiogenic therapy, n(%) | Â | Â | 0.891 |
 No | 23(76.7) | 25(78.1) |  |
 Yes | 7(23.3) | 7(21.9) |  |
cTNM stage, n(%) | Â | Â | 0.090 |
 III | 6(20) | 1(3.1) |  |
 IV | 24(80) | 31(96.9) |  |
Smoking habits, n(%) | Â | Â | 0.023 |
 Non-smoker | 12(40) | 22(68.8) |  |
 ex-smoker | 18(60) | 10(31.2) |  |